In vitro pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 863-874

  Malysz, John ^a   Anderson, David J ^a   Grønlien, Jens H ^b   Ji, Jianguo ^a   Bunnelle, William H ^a   Håkerud, Monika ^b   Thorin Hagene, Kirten ^b   Ween, Hilde ^b   Helfrich, Rosalind ^a   Hu, Min ^a   Gubbins, Earl ^a   Gopalakrishnan, Sujatha ^a   Puttfarcken, Pamela S ^a   Briggs, Clark A ^a   Li, Jinhe ^a   Meyer, Michael D ^a   Dyhring, Tino ^c   Ahring, Philip K ^c   Nielsen, Elsebet Ø ^c   Peters, Dan ^c   Timmermann, Daniel B ^c   Gopalakrishnan, Murali ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b Research and Development   (Norway)

^c NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 DIMETHYL 5 (6 PHENYLPYRIDAZIN 3 YL) 5 AZA 2 AZONIABICYCLO[2.2.1]HEPTANE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; 4 [5 (4 CHLOROPHENYL) 2 METHYL 3 PROPIONYLPYRROL 1 YL]BENZENESULFONAMIDE; 5 [6 (1 AZABICYCLO[2,2,2]OCT 3 YLOXY)PYRIDAZIN 3 YL] 1H INDOLE; A 585539; A 867744; ABT 107; BUNGAROTOXIN RECEPTOR; CALCIUM ION; GLUTAMIC ACID; METHYLLYCACONITINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA4BETA4; PNU 120596; UNCLASSIFIED DRUG; 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-METHYLISOXAZOL-3-YL)UREA; 4-(5-(4-CHLOROPHENYL)-2-METHYL-3-PROPIONYL-1H-PYRROL-1-YL)BENZENESULFONAMIDE; 5-(6-(1-AZABICYCLO(2,2,2)OCT-3-YLOXY)PYRIDAZIN-3-YL)-1H-INDOLE; AMINO ACID RECEPTOR BLOCKING AGENT; CALCIUM; CARBANILAMIDE DERIVATIVE; CHRNA7 PROTEIN, HUMAN; CHRNA7 PROTEIN, RAT; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PYRROLE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CALCIUM SIGNALING; CONTROLLED STUDY; CYTOTOXICITY; DENTATE GYRUS; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; EXCITATORY POSTSYNAPTIC POTENTIAL; GRANULE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BRAIN CORTEX; CELL CULTURE; CELL LINE; DRUG EFFECTS; ELECTROPHYSIOLOGY; ENZYME SPECIFICITY; MALE; METABOLISM; PATCH CLAMP TECHNIQUE; PC12 CELL LINE; PHOSPHORYLATION; RADIOASSAY; SPRAGUE DAWLEY RAT; XENOPUS;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; CALCIUM; CELL LINE; CELLS, CULTURED; CEREBRAL CORTEX; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; ISOXAZOLES; MALE; NICOTINIC AGONISTS; OOCYTES; PATCH-CLAMP TECHNIQUES; PC12 CELLS; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PYRROLES; QUINUCLIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SUBSTRATE SPECIFICITY; SULFONAMIDES; XENOPUS;

EID: 77956239822     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167072     Document Type: Article

References (39)

1. Albuquerque EX, Pereira EF, Alkondon M, and Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73-120.
2. Alkondon M, Braga MF, Pereira EF, Maelicke A, and Albuquerque EX (2000) alpha7 nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol 393:59-67.
3. Anderson DJ, Bunnelle W, Surber B, Du J, Surowy C, Tribollet E, Marguerat A, Bertrand D, and Gopalakrishnan M (2008) [3H]A-585539 [(1S,4S)-2,2-dimethyl- 5- (6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptanes], a novel high affinity alpha7 neuronal nicotinic receptor agonist: radioligand biding characterization to rat and human brain. J Pharmacol Exp Ther 324:179-187.
4. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, et al. (2007) Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27:10578-10587.
5. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Nikkel AL, Buccafusco JJ and Gopalakrishnan M. (2010) The novel alpha7 nAChR agonist ABT-107 produces preclinical cognitive efficacy and activation of neurochemical and cellular pathways suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. J Pharmacol Exp Ther, 334:875-886.
6. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 32:1-16.
7. Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, Higdon NR, Hoffmann WE, Hurst RS, Myers JK, et al. (2005) Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem 48:905-908.
8. Briggs CA, Grønlien JH, Curzon P, Timmermann DB, Ween H, Thorin-Hagene K, Kerr P, Anderson DJ, Malysz J, Dyhring T, et al. (2009) Role of channel activation in alpha7 nAChR-mediated cognitive enhancement. Br J Pharmacol 158:1486-1494.
9. Briggs CA and McKenna DG (1998) Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 37: 1095-1102.
10. Dani JA and Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699-729.
11. El Kouhen R, Hu M, Anderson DJ, Li J, and Gopalakrishnan M (2009) Pharmacology of alpha7 nicotinic acetylcholine receptor mediated extracellular signal-regulated kinase signalling in PC12 cells. Br J Pharmacol 156:638-648.
12. Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, et al. (2009) The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 56:254-263.
13. Frazier CJ, Buhler AV, Weiner JL, and Dunwiddie TV (1998) Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 18:8228-8235.
14. 2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 35:1-8.
15. Grønlien JH, Håkerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, and Malysz J (2007) Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72: 715-724.
16. Hajós M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, and Groppi VE (2005) The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312:1213-1222.
17. Hansen HH, Timmermann DB, Peters D, Walters C, Damaj MI, and Mikkelsen JD (2007) Alpha7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. J Neurosci Res 85:1810-1818.
18. Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, Stachowiak EK, Stachowiak MK, Papke RL, Lippiello PM, et al. (2009) TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78:803-812.
19. Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, La Rosa S, Micco I, Pollastrini M, Quinn J, et al. (2009) SAR and biological evaluation of SEN12333/WAY-317538: novel alpha7 nicotinic acetylcholine receptor agonist. Bioorg Med Chem 17:5247-5258.
20. Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, et al. (2005) A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25:4396-4405.
21. Jørgensen S, Nielsen EØ, Peters D, and Dyhring T (2008) Validation of a fluorescence- based high-throughput assay for the measurement of neurotransmitter transporter uptake activity. J Neurosci Methods 169:168-176.
22. Kuryatov A, Olale F, Cooper J, Choi C, and Lindstrom J (2000) Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses. Neuropharmacology 39:2570-2590.
23. Levin ED and Rezvani AH (2002) Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 1:423-431.
24. Lopez-Hernandez G, Placzek AN, Thinschmidt JS, Lestage P, Trocme-Thibierge C, Morain P, and Papke RL (2007) Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 53:134-144.
25. Lukas RJ (1986) Characterization of curaremimetic neurotoxin binding sites on membrane fractions derived from the human medulloblastoma clonal line, TE671. J Neurochem 46:1936-1941.
26. Malysz J, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, Ween H, Wetterstrand C, Briggs CA, Faghih R, Bunnelle WH, et al. (2009a) In vitro pharmacological characterization of a novel allosteric modulator of alpha7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H- pyrrol- 1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther 330:257-267.
27. Malysz J, Gronlien JH, Timmermann D, Hakerud M, Thorin-Hagene K, Ween H, Trumbull JD, Xiong Y, Briggs CA, Ahring PK, et al. (2009b) Evaluation of alpha7 nicotinic acetylcholine receptor agonists and positive allosteric modulators using Parallel Oocyte Electrophysiology Test Station (POETS). Assay Drug Develop Technol 7:374-390.
28. Manelli AM and Puttfarcken PS (1995) beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Res Bull 38:569-576.
29. Mullen G, Napier J, Balestra M, DeCory T, Hale G, Macor J, Mack R, Loch J 3rd, Wu E, Kover A, et al. (2000) (-)-Spiro[1-azabicyclo[2.2.2]octane-3, 5′-oxazolidin-2′- one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 43:4045-4050.
30. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34.
31. 3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 33:269-275.
32. Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, et al. (2009) Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neuro-degenerative and cognitive disorders. J Pharmacol Exp Ther 329:459-468.
33. Steinlein OK and Bertrand D (2008) Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases. Biochem Pharmacol 76:1175-1183.
34. Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14:311-317.
35. Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C, Jonak G, Gurley D, Gordon JC, Christian EP, et al. (2009) Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 78:880-888.
36. Taly A, Corringer PJ, Guedin D, Lestage P, and Changeux JP (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8:733-750.
37. Tietje KR, Anderson DJ, Bitner RS, Blomme EA, Brackemeyer PJ, Briggs CA, Browman KE, Bury D, Curzon P, Drescher KU, et al. (2008) Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther 14: 65-82.
38. 2+ transient generation in IMR-32 neuroblastoma cells. Neurochem Int 57:269-277.
39. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, et al. (2006) Discovery of N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. J Med Chem 49:4425-4436.